在其他近期新闻中，Tiziana Life Sciences在开发免疫疗法方面取得了重大进展。公司的鼻内抗CD3单克隆抗体foralumab在减轻GLP-1激动剂（常用于代谢紊乱治疗）的副作用方面显示出潜力。Tiziana的疗法旨在抵消这些激动剂的副作用，可能改善患者的长期预后。

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

NEW YORK - Tiziana Life Sciences Ltd. (NASDAQ:TLSA), a biotech firm focused on immunomodulation therapies with a market ...

Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, commented, “Treatment with nasal anti-CD3 not only dampened microglial activation but also led to marked improvements in ...

Shares of Tiziana Life Sciences rose after the company said it received positive results from its nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury. The stock was up 5.3% to 84 cents ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

New York-based biotech Tiziana Life Sciences today announces its intention not to engage in a capital raising activities for the immediate future.

Tiziana的新任首席执行官Ivor Elrifi正在领导鼻内foralumab的持续临床试验。Tiziana获得了340万美元的非稀释性资金，用于推进其鼻内foralumab治疗na-SPMS的2期临床试验。公司还扩大了其MS治疗的2期试验，FDA批准增加20名患者。

Tiziana Life Sciences (TLSA) announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple ...

Tiziana Life Sciences is developing foralumab, an anti-CD3 monoclonal antibody, for treating neurodegenerative diseases like SPMS and Alzheimer's, with promising early results. Positive Phase 2 ...

Tiziana Life Sciences, Ltd. has announced the publication of a review article in Nature Reviews Neurology, which highlights the potential of its lead drug candidate, intranasal foralumab ...

We've identified the following companies as similar to Tiziana Life Sciences Ltd because they operate in a related industry or sector. We also considered size, growth, and various financial ...